In what medical researchers are calling a major milestone for genetic medicine, a first-in-human Phase 1 clinical trial conducted by the Cleveland Clinic has demonstrated that a single infusion of a CRISPR-Cas9 gene-editing therapy can produce profound and lasting reductions in both low-density lipoprotein—commonly known as LDL or "bad" cholesterol—and triglycerides. The groundbreaking findings offer new hope for individuals struggling with severe lipid disorders that have proven resistant to conventional medications.
The study followed a cohort of 15 patients over a full year to determine whether the impressive cholesterol and triglyceride reductions initially observed after two months would prove durable over time. The results, which were unveiled at the 2026 European Society of Cardiology annual meeting and published simultaneously in the New England Journal of Medicine, confirmed that the therapeutic benefits not only persisted but remained stable throughout the 12-month monitoring period.
Participants who received the highest dose of the experimental treatment experienced a striking 52.5% reduction from their baseline LDL cholesterol levels, alongside a 47.8% drop in triglycerides. Furthermore, clinical investigators reported that no serious adverse events related to the therapy occurred during the entire one-year follow-up window, marking a critical early safety milestone for the in vivo gene-editing candidate.
Cholesterol Reductions Lasted for a Year
The durability of the lipid-lowering effect has electrified the cardiology community, particularly given the lifelong challenge of managing treatment-resistant dyslipidemia. Traditional therapies, such as statins, ezetimibe, and PCSK9 inhibitors, often require daily or bi-weekly administration and can sometimes fall short for patients with complex genetic lipid disorders.
"Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive," said Cleveland Clinic cardiologist Luke Laffin, M.D., who served as the first author of the study. "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients."
The technology underlying the treatment, CRISPR-Cas9, represents a revolutionary leap forward in modern biotechnology. Originally derived from a natural defense mechanism found in bacteria, CRISPR-Cas9 functions as a molecular scalpel, allowing scientists to make precise, targeted modifications to specific sequences within a person’s DNA. In the realm of medical research, scientists are increasingly studying this gene-editing platform as a transformative approach to treating severe, refractory diseases by permanently altering the underlying genetic drivers that contribute to those conditions.
How CTX310 Targets Blood Fats
The experimental therapeutic evaluated in the trial, designated as CTX310, is engineered to be administered as a singular, one-time intravenous infusion. Rather than targeting circulating lipids indirectly, the therapy delivers the CRISPR-Cas9 gene-editing system directly to the liver—the primary metabolic hub for processing fats in the human body. Once inside the hepatic cells, the therapy selectively deactivates a specific gene known as ANGPTL3.
The ANGPTL3 gene plays a critical regulatory role in controlling the metabolism of various fats circulating in the bloodstream. By disabling this specific gene, the therapy effectively halts the production of the ANGPTL3 protein, which in turn leads to a substantial decline in both LDL cholesterol and triglycerides. Elevated levels of both biomarkers are independently and jointly recognized as major independent risk factors for the development and progression of cardiovascular disease, including atherosclerosis, heart attacks, and strokes.
During the execution of the Phase 1 trial, patients were administered CTX310 across a range of escalating doses, spanning from 0.1 to 0.8 mg/kg, designed to assess the safety threshold and identify the optimal therapeutic window. To mitigate potential acute immune or infusion-related reactions, participants were pre-treated with standard courses of corticosteroids and antihistamines prior to receiving the gene-editing infusion.
Following the procedure, clinical researchers maintained rigorous oversight, continuously monitoring participants for any signs of adverse safety events while regularly measuring systemic changes in ANGPTL3 protein expression, LDL cholesterol concentrations, and overall triglyceride levels. By the conclusion of the 12-month evaluation period, patients in the highest dosage cohort demonstrated an average reduction of approximately 50% in both primary lipid metrics, confirming a powerful and sustained metabolic shift.
Long-Term Monitoring Will Continue
Despite the profound optimism generated by the one-year outcomes, medical experts emphasize that CTX310 remains strictly experimental, and the current study’s scope was intentionally limited to a small cohort of 15 participants to establish initial human safety and pharmacokinetic profiles.
In strict adherence to regulatory guidelines and recommendations set forth by the U.S. Food and Drug Administration (FDA) for all clinical evaluations involving human gene-editing technologies, the trial participants will continue to be monitored under a long-term safety follow-up protocol. This extended observation period will span an additional 15 years to ensure that any potential delayed or long-term systemic effects are comprehensively documented and evaluated.
The clinical trial was sponsored and financially supported by CRISPR Therapeutics AG, based in Zug, Switzerland. Additionally, disclosures note that Dr. Laffin’s home institution, the Cleveland Clinic, has received research funding from CRISPR Therapeutics to support ongoing scientific investigation into genetic cardiovascular therapies.
